Referencias a artículos incluidos en PubMed que los socios consideren de especial interés. Si deseas colaborar, envía la referencia recomendada, indicando tu nombre y centro de trabajo, a la siguiente dirección de correo electrónico:
secretariosvpd@gmail.com
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. [PubMed]
[2-7-2012. José Joaquín Ramírez. Hospital Lluis Alcanyis, Xàtiva]Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012 Jan;142(1):63-70.e5 [PubMed]
[20-2-2012. José Joaquín Ramírez. Hospital Lluis Alcanyis, Xàtiva]
Cure S, Diels J, Gavart S, Bianic F, Jones E. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients : an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin. 2012 Sep 27. [Epub ahead of print] [PubMed]
[29-9-2012. Joaquín Primo. Hospital de Sagunto]Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O’Regan C, Mills EJ. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag. 2012;8:105-30. [PubMed]
[29-9-2012. Joaquín Primo. Hospital de Sagunto]Rowe IA, Houlihan DD, Mutimer DJ. Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Aliment Pharmacol Ther. 2012 Oct;36(7):670-9. [PubMed]
[29-9-2012. Joaquín Primo. Hospital de Sagunto]Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, Nicastri PL, Locatelli A, Floreani A, Hernandez I, Di Martino V. Efficacy of Ursodeoxycholic Acid in Treating Intrahepatic Cholestasis of Pregnancy: a Meta-Analysis. Gastroenterology. 2012 Aug 11. [Epub ahead of print] [PubMed]
[18-8-2012. Joaquín Primo. Hospital de Sagunto]Leroy V, Serfaty L, Bourlière M, Bronowicki JP, Delasalle P, Pariente A, Pol S, Zoulim F, Pageaux GP. Protease inhibitor-based triple therapy in chronic hepatitis C: Guidelines by the French association for the study of the Liver. Liver Int. 2012 Aug 14. doi: 10.1111/j.1478-3231.2012.02856.x. [Epub ahead of print] [PubMed]
[18-8-2012. Joaquín Primo. Hospital de Sagunto]Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012 Jul 18. [Epub ahead of print] [PubMed]
[30-7-2012. Joaquín Primo. Hospital de Sagunto]Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V; on behalf of the Definitions/Nomenclature Working Group* of the HCV DrAG (HCV Drug Development Advisory Group), under the auspices of the Forum for Collaborative HIV Research. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology. 2012 Jun 18. doi: 10.1002/hep.25888. [Epub ahead of print] [PubMed]
[23-6-2012. Joaquín Primo. Hospital de Sagunto]El Khoury AC, Vietri J, Prajapati G. The Burden of Untreated Hepatitis C Virus Infection: A US Patients’ Perspective. Dig Dis Sci. 2012 Jun 5. [Epub ahead of print] [PubMed]
[17-6-2012. Joaquín Primo. Hospital de Sagunto]Albeldawi M, Soliman M, Lopez R, Zein NN. Hepatitis C Virus-Associated Primary Hepatocellular Carcinoma in Non-cirrhotic Patients. Dig Dis Sci. 2012 Jun 14. [Epub ahead of print] [PubMed]
[17-6-2012. Joaquín Primo. Hospital de Sagunto]Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Jun 12. doi: 10.1038/ajg.2012.137. [Epub ahead of print] [PubMed]
[17-6-2012. Joaquín Primo. Hospital de Sagunto]Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O’Regan C, Mills EJ. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag. 2012;8:105-30. [PubMed]
[17-6-2012. Joaquín Primo. Hospital de Sagunto]Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators. Factors that Predict Response of Patients with HCV Infection to Boceprevir. Gastroenterology. 2012 May 21. [Epub ahead of print] [PubMed]
[26-5-2012. Joaquín Primo. Hospital de Sagunto]Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, Dinubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP. Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin. Hepatology. 2012 May 22. doi: 10.1002/hep.25865. [Epub ahead of print] [PubMed]
[26-5-2012. Joaquín Primo. Hospital de Sagunto]Hulskotte E, Gupta S, Xuan F, van Zutven M, O’Mara E, Feng HP, Wagner J, Butterton J. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012 May 11. doi: 10.1002/hep.25831. [Epub ahead of print] [PubMed]
[12-5-2012. Joaquín Primo. Hospital de Sagunto]Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat. 2012 Jun;19(6):377-86. [PubMed]
[12-5-2012. Joaquín Primo. Hospital de Sagunto]Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C. J Viral Hepat. 2012 Apr;19(4):244-253. [PubMed]
[13-4-2012. Joaquín Primo. Hospital de Sagunto]Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012 Feb 1. doi: 10.1111/j.1365-2036.2012.04992.x. [Epub ahead of print] [PubMed]
[7-2-2012. Joaquín Primo. Hospital de Sagunto]Muir AJ, Poordad FF, McHutchison JG, Shiffman ML, Berg T, Ferenci P, Heathcote EJ, Pawlotsky JM, Zeuzem S, Reesink HW, Dusheiko G, Martin EC, George S, Kauffman RS, Adda N. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011 Nov;54(5):1538-46. [PubMed]
[30-1-2012. Joaquín Primo. Hospital de Sagunto]